A world first program designed to help medical researchers in type one diabetes develop their leadership skills to help take innovations out of the lab and into the real world has graduated its first intake. The graduates, announced in Canberra on June 26th 2018, have already put their skills into practice, securing funding to look at a dietary supplement that could stop type one diabetes. Read More
Two promising research projects have been targeted to receive contract seed funding grants, and will benefit from $350K in funding from the Type 1 Diabetes Clinical Research Network (T1DCRN), itself an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC).
These two projects will explore new directions in curing and treating T1D and its complications. Read More
Senator The Hon Simon Birmingham, Minister for Education and Training, and The Hon Greg Hunt MP, Minister for Health and Minister for Sport, have today announced the recipients of Innovation Award grants for research into type 1 diabetes.
Three bold, promising research projects have been selected and will benefit from $4.5 million in funding from the Type 1 Diabetes Clinical Research Network (T1DCRN), itself an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC).
In an exciting paradigm shift that aims to accelerate patient impact, the research funded by the Innovation Award grants will explore new directions in the search for a cure for type 1 diabetes, including concepts that have never before been investigated.
The Australian Type 1 Diabetes Clinical Research Network has partnered with the Immune Tolerance Network to launch a new Australian clinical trial to slow the development of newly diagnosed type 1 diabetes in children.
The EXTEND-P trial is expected to begin recruitment in March 2016 to test the ability of an existing drug called tocilizumab to preserve beta cell function. Tocilizumab, sold under the brand name Actemra, is currently approved for use in children with juvenile arthritis. Read More
A new technique that could drastically improve outcomes of human islet transplantation has been successful in a world-first clinical trial.
The technique, developed by the US-based Diabetes Research Institute (DRI) and supported in part by JDRF funding, involves transplanting islets in a biodegradable ‘scaffold’ into the omentum, a fold of tissue that covers and protects the abdominal organs. Read More